NEW YORK - The drugmaker Eli Lilly & Co. says it has agreed to buy biotechnology company ImClone Systems Inc. for more than $6 billion in a deal that would expand its pipeline of cancer treatments.
Indianapolis-based Lilly said Monday it will pay $70 per share for ImClone. With about 87 million shares outstanding as of Aug. 1, that would amount to nearly $6.1 billion. Lilly said the transaction is worth $6.5 billion.
New York-based ImClone had previously rejected as too low two takeover offers from Bristol-Myers Squibb Co., its marketing partner for the cancer drug Erbitux. Bristol-Myers made bids of $60 and later of $62 per share.
ImClone says Chairman Carl Icahn, who owns about 14 percent of ImClone stock, has agreed to vote in favor of the Lilly deal.
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or email@example.com.